GSK, Shenzhen Neptunus Of China To Collaborate On Flu Vaccines
This article was originally published in PharmAsia News
Executive Summary
U.K.-based GlaxoSmithKline and China's Shenzhen Neptunus plan a joint venture to make influenza vaccines in China, with GSK holding a 40 percent stake with options to buy more. The deal is expected to increase the British company's presence in China where it hopes to trade on its adjuvant technology. The five-year plan for the joint venture calls for production of seasonal, pre-pandemic and pandemic flu vaccine for China, Hong Kong and Macau. GSK also intends to expand its vaccine-manufacturing business in other parts of Asia. (Click here for more